Pediatric Intensive Care Unit, Children's Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China.
Int J Infect Dis. 2012 Aug;16(8):e628-32. doi: 10.1016/j.ijid.2012.03.014. Epub 2012 Jun 17.
Pediatric Pseudomonas aeruginosa bacteremia is uncommon. It is mostly seen with impaired immune defenses and is most often nosocomially acquired, but it does occasionally occur in the previously healthy. Empiric antibiotics not effective against P. aeruginosa can result in poor outcomes. To determine the risk factors for P. aeruginosa bacteremia, all pediatric cases of P. aeruginosa bacteremia hospitalized at a single center over a 5-year period were reviewed.
A retrospective cohort study (2006-2010) of P. aeruginosa bacteremia in children under 14 years of age assessing demographics, the presence of underlying diseases, whether nosocomially acquired, clinical and laboratory findings, P. aeruginosa antibiotic susceptibility, antibiotic therapy, and clinical outcomes was performed.
Thirty-one children, mean age 46 months, had P. aeruginosa bacteremia (2.6% positive blood cultures); 18 cases were nosocomial, none were multi-resistant, and 13 (42%) had P. aeruginosa isolated from a site other than blood. Ten cases occurred in previously healthy children, all of which were community-acquired, and these children were more likely to present with seizures and gastrointestinal findings than those with underlying conditions. The overall case fatality rate was 52% (16/31); 6/16 were previously healthy. Fatal cases had more leukopenia, elevated aspartate aminotransferase, and lower prealbumin A. Fewer fatal cases (6/16 vs. 14/15) had initial antibiotic coverage effective for P. aeruginosa (p=0.002). No difference in case fatality rate (p>0.05) or antibiotic sensitivity (p>0.05) was found between community-acquired and nosocomial cases.
P. aeruginosa bacteremia in children is rare but often fatal if initial antibiotics do not cover P. aeruginosa. Factors indicative of P. aeruginosa bacteremia remain elusive, especially in previously healthy young children. However, P. aeruginosa bacteremia should be considered if children present with a grave illness, seizures, serious gastrointestinal findings, hypotension, and leukopenia.
儿童铜绿假单胞菌菌血症并不常见。它主要发生在免疫防御受损的情况下,通常是医院获得性的,但偶尔也会发生在健康的儿童身上。如果使用的经验性抗生素对铜绿假单胞菌无效,可能会导致不良后果。为了确定铜绿假单胞菌菌血症的危险因素,对一家中心 5 年来所有住院的儿童铜绿假单胞菌菌血症病例进行了回顾性队列研究(2006-2010 年),评估了人口统计学特征、潜在疾病的存在、是否为医院获得性感染、临床和实验室发现、铜绿假单胞菌抗生素敏感性、抗生素治疗和临床结局。
对 14 岁以下儿童的铜绿假单胞菌菌血症进行回顾性队列研究(2006-2010 年),评估人口统计学特征、潜在疾病、是否为医院获得性感染、临床和实验室发现、铜绿假单胞菌抗生素敏感性、抗生素治疗和临床结局。
31 名儿童,平均年龄 46 个月,发生铜绿假单胞菌菌血症(血培养阳性率为 2.6%);18 例为医院获得性感染,无多重耐药菌,13 例(42%)铜绿假单胞菌从血液以外的部位分离。10 例发生在健康的儿童,均为社区获得性感染,这些儿童比有潜在疾病的儿童更有可能出现癫痫发作和胃肠道表现。总的病死率为 52%(16/31);6/16 为健康儿童。死亡病例白细胞减少、天门冬氨酸转氨酶升高、前白蛋白 A 降低更为明显。较少的死亡病例(6/16 例比 14/15 例)初始抗生素治疗对铜绿假单胞菌有效(p=0.002)。社区获得性和医院获得性病例的病死率(p>0.05)或抗生素敏感性(p>0.05)无差异。
儿童铜绿假单胞菌菌血症罕见,但如果初始抗生素不能覆盖铜绿假单胞菌,则往往致命。儿童铜绿假单胞菌菌血症的危险因素仍不明确,尤其是在健康的幼儿中。然而,如果儿童出现严重疾病、癫痫发作、严重胃肠道表现、低血压和白细胞减少,应考虑铜绿假单胞菌菌血症。